Recital 2, Commission Implementing Regulation (EU) No 198/2013 of 7 March 2013 on the selection of…

In forcesince 7 Mar 2013

Patients and healthcare professionals should be able to easily identify medicinal products that are subject to additional monitoring in order to allow them to share with the competent authorities and the marketing authorisation holder any information they have from the use of the medicinal product and in particular to report suspected adverse reactions.